Association between psychosis and substance use in Kenya. Findings from the NeuroGAP-Psychosis study.

bipolar mood disorders cases controls psychosis schizophrenia substance use disorders

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2024
Historique:
received: 25 09 2023
accepted: 06 02 2024
medline: 19 3 2024
pubmed: 19 3 2024
entrez: 19 3 2024
Statut: epublish

Résumé

Substance use is prevalent among people with mental health issues, and patients with psychosis are more likely to use and misuse substances than the general population. Despite extensive research on substance abuse among the general public in Kenya, there is a scarcity of data comparing substance use among people with and without psychosis. This study investigates the association between psychosis and various substances in Kenya. This study utilized data from the Neuro-GAP Psychosis Case-Control Study between April 2018 and December 2022. The KEMRI-Wellcome Trust Research Programme recruited participants from various sites in Kenya, including Kilifi County, Malindi Sub-County, Port Reitz and Coast General Provincial Hospitals, and Moi Teaching and Referral Hospital, as well as affiliated sites in Webuye, Kapenguria, Kitale, Kapsabet, and Iten Kakamega. The collected data included sociodemographic information, substance use, and clinical diagnosis. We used the summary measures of frequency (percentages) and median (interquartile range) to describe the categorical and continuous data, respectively. We examined the association between categorical variables related to psychosis using the chi-square test. Logistic regression models were used to assess the factors associated with the odds of substance use, considering all relevant sociodemographic variables. We assessed a total of 4,415 cases and 3,940 controls. Except for alcohol consumption (p-value=0.41), all forms of substance use showed statistically significant differences between the case and control groups. Cases had 16% higher odds of using any substance than controls (aOR: 1.16, 95%CI: 1.05-1.28, p=0.005). Moreover, males were 3.95 times more likely to use any substance than females (aOR:3.95; 95%CI: 3.43-4.56). All the categories of living arrangements were protective against substance use. The findings of this study suggest that psychotic illnesses are associated with an increased likelihood of using various substances. These findings are consistent with those of previous studies; however, it is crucial to investigate further the potential for reverse causality between psychosis and substance abuse using genetically informed methods.

Sections du résumé

Background UNASSIGNED
Substance use is prevalent among people with mental health issues, and patients with psychosis are more likely to use and misuse substances than the general population. Despite extensive research on substance abuse among the general public in Kenya, there is a scarcity of data comparing substance use among people with and without psychosis. This study investigates the association between psychosis and various substances in Kenya.
Methods UNASSIGNED
This study utilized data from the Neuro-GAP Psychosis Case-Control Study between April 2018 and December 2022. The KEMRI-Wellcome Trust Research Programme recruited participants from various sites in Kenya, including Kilifi County, Malindi Sub-County, Port Reitz and Coast General Provincial Hospitals, and Moi Teaching and Referral Hospital, as well as affiliated sites in Webuye, Kapenguria, Kitale, Kapsabet, and Iten Kakamega. The collected data included sociodemographic information, substance use, and clinical diagnosis. We used the summary measures of frequency (percentages) and median (interquartile range) to describe the categorical and continuous data, respectively. We examined the association between categorical variables related to psychosis using the chi-square test. Logistic regression models were used to assess the factors associated with the odds of substance use, considering all relevant sociodemographic variables.
Results UNASSIGNED
We assessed a total of 4,415 cases and 3,940 controls. Except for alcohol consumption (p-value=0.41), all forms of substance use showed statistically significant differences between the case and control groups. Cases had 16% higher odds of using any substance than controls (aOR: 1.16, 95%CI: 1.05-1.28, p=0.005). Moreover, males were 3.95 times more likely to use any substance than females (aOR:3.95; 95%CI: 3.43-4.56). All the categories of living arrangements were protective against substance use.
Conclusion UNASSIGNED
The findings of this study suggest that psychotic illnesses are associated with an increased likelihood of using various substances. These findings are consistent with those of previous studies; however, it is crucial to investigate further the potential for reverse causality between psychosis and substance abuse using genetically informed methods.

Identifiants

pubmed: 38501084
doi: 10.3389/fpsyt.2024.1301976
pmc: PMC10945606
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1301976

Informations de copyright

Copyright © 2024 Nguata, Orwa, Kigen, Kamaru, Emonyi, Kariuki, Newton, Ongeri, Mwende, Gichuru and Atwoli.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Monica Nguata (M)

Department of Post Traumatic Stress Disorder (PTSD) Tnx, Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.

James Orwa (J)

Department of Population Health, Medical College of East Africa Aga Khan University, Nairobi, Kenya.

Gabriel Kigen (G)

Department of Pharmacology and Toxicology, Moi University School of Medicine, Eldoret, Kenya.

Edith Kamaru (E)

Department of Mental Health, Moi Teaching and Referral Hospital, Eldoret, Kenya.

Wilfred Emonyi (W)

Department of Immunology, Moi University School of Medicine, Eldoret, Kenya.

Symon Kariuki (S)

Neuroscience Unit, Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya.
Department of Public Health, Pwani University, Kilifi, Kenya.
Department of Psychiatry, University of Oxford, Oxford, United Kingdom.

Charles Newton (C)

Neuroscience Unit, Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya.
Department of Public Health, Pwani University, Kilifi, Kenya.
Department of Psychiatry, University of Oxford, Oxford, United Kingdom.

Linnet Ongeri (L)

Neuroscience Unit, Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya.

Rehema Mwende (R)

Neuroscience Unit, Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya.
Department of Public Health, Pwani University, Kilifi, Kenya.
Department of Psychiatry, University of Oxford, Oxford, United Kingdom.

Stella Gichuru (S)

Department of Medicine, Medical College East Africa, the Aga Khan University, Nairobi, Kenya.

Lukoye Atwoli (L)

Department of Medicine, Medical College East Africa, the Aga Khan University, Nairobi, Kenya.
Department of Mental Health and Behavioural Sciences, Moi University School of Medicine, Eldoret, Kenya.
Brain and Mind Institute, the Aga Khan University, Nairobi, Kenya.

Classifications MeSH